Multiple myeloma in the elderly patients:From frailty assessment to progress in Immunotherapy

被引：1
|
作者：
Facon, T. [1 ]
Manier, S. [1 ]
机构：
[1] CHU Lille, Hop Claude Huriez, Serv dhematol, 2 Ave Oscar Lambret, F-59037 Lille, France
来源：
BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE | 2022年 / 206卷 / 08期
关键词：
Multiple myeloma; Drug Therapy; Therapy; Immunotherapy; Oncogeriatry; Frail elderly patient; STEM-CELL TRANSPLANTATION; OPEN-LABEL; GERIATRIC ASSESSMENT; DEXAMETHASONE; BORTEZOMIB; MELPHALAN; LENALIDOMIDE; PREDNISONE; PHASE-3; DARATUMUMAB;
D O I：
10.1016/j.banm.2022.07.006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Multiple myeloma is primarily a disease of the elderly patients. Geriatric aspects have been poorly investigated until recently. Frailty assessment is now more frequent and will be useful in the context of significant and sustained therapeutic progress. The recent emergence of immunotherapy with CD38 monoclonal antibodies and upcoming immuno-oncology drugs such as bispecific antibodies will lead to additional progress. The applicability of these complex molecules to elderly and frail patients is a key clinical question.(c) 2022 l'Academie nationale de medecine. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：966 / 972
页数：7
相关论文
共 50 条
  • [21] Treatment patterns and clinical outcomes for multiple myeloma in Korean patients: a database study
    Yoon, Junghyun
    Jung, Jongheon
    Park, Boyoung
    Lee, Eunyoung
    Park, Youngju
    Yoon, Soomin
    Eom, Hyeon-Seok
    BMC CANCER, 2025, 25 (01)
  • [22] Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database
    LeBlanc, Richard
    Mian, Hira
    Reece, Donna
    Masih-Khan, Esther
    Kardjadj, Moustafa
    Jimenez-Zepeda, Victor H.
    McCurdy, Arleigh
    Song, Kevin
    Sebag, Michael
    Louzada, Martha
    White, Darrell
    Stakiw, Julie
    Kotb, Rami
    Reiman, Anthony
    Aslam, Muhammad
    Gul, Engin
    Venner, Christopher P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (01) : 93 - 102
  • [23] New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma
    Neri, Paola
    Bahlis, Nizar J.
    Lonial, Sagar
    CLINICAL CANCER RESEARCH, 2016, 22 (24) : 5959 - 5965
  • [24] Immunotherapy in Multiple Myeloma
    Soekojo, Cinnie Yentia
    Ooi, Melissa
    de Mel, Sanjay
    Chng, Wee Joo
    CELLS, 2020, 9 (03)
  • [25] A Markov model for estimating the cost-effectiveness of immunotherapy for newly diagnosed multiple myeloma patients
    Bilancia, Massimo
    Solimando, Antonio Giovanni
    Manca, Fabio
    Vacca, Angelo
    Ria, Roberto
    COMPUTATIONAL STATISTICS & DATA ANALYSIS, 2025, 206
  • [26] Daratumumab utilization and cost analysis among patients with multiple myeloma in a US community oncology setting
    Gordan, Lucio N.
    Marks, Stanley M.
    Xue, Mei
    Nagovski, Neil
    Lambert, J. Hunter
    Smith, Robert E.
    FUTURE ONCOLOGY, 2021, 18 (03) : 301 - 309
  • [27] Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
    Ackley, James
    Ochoa, Miguel Armenta
    Ghoshal, Delta
    Roy, Krishnendu
    Lonial, Sagar
    Boise, Lawrence H.
    CANCERS, 2021, 13 (19)
  • [28] Advances in immunotherapy in multiple myeloma
    Boussi, Leora
    Niesvizky, Ruben
    CURRENT OPINION IN ONCOLOGY, 2017, 29 (06) : 460 - 466
  • [29] MRD Assessment in Multiple Myeloma: Progress and Challenges
    Bertamini, Luca
    D'Agostino, Mattia
    Gay, Francesca
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2021, 16 (02) : 162 - 171
  • [30] Frailty in multiple myeloma: the need for harmony to prevent doing harm
    Zweegman, Sonja
    Larocca, Alessandra
    LANCET HAEMATOLOGY, 2019, 6 (03): : E117 - E118
12345